Keywords: Stallergenes, Ares Life Sciences, Wendel, Respirtory allegies, M&A

Ares Life Sciences aims to take full control of Stallergenes, having already bought Wendel’s 46% stake in the firm

Article | 18 November 2010

Print This

Having earlier this month bought investment firm Wendel’s 45.86% equity interest in Stallergenes (GENP: PA) for 59 euros a share, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in